Heart development requires precise temporal-spatial regulation of gene expression, in which the highly conserved modulation networks of transcription factors accurately control the signaling pathways required for normal cardiovascular development. Even slight perturbation of such programming during cardiogenesis can cause congenital heart defects and late neonatal or adult heart disease. microRNAs (miRNAs), a class of "small" non-coding RNAs, have recently drawn a lot of attention for their "big" impact on cardiovascular development and diseases. miRNAs negatively regulate the expression of their target genes in most biological organisms through posttranscriptional processes. Here, we review the roles of miRNAs in cardiovascular development and function, looking inside the molecular mechanisms by which miRNAs act as "fine tuners" and/or "safeguards" to maintain the homeostasis of cardiovascular system. We also propose new directions for therapeutic potential of these tiny molecules.
Introduction
The heart is the first organ to form during mammalian embryonic development [1] [2] . In the mouse, cardiogenesis begins when a population of cells in the mesoderm commit to a cardiogenic fate at embryonic day 7.5 (E7.5). These cardiac cells, localized to the cardiac crescent, migrate ventromedially to form linear heart tube at E8.0. Shortly after E8.0, rhythmic contractions occur. Subsequent events of looping morphogenesis, chamber specification, cardiac valve formation, and neural crest cell migration and contribution give rise to the multi-chambered heart by E10.5 [1] . Heart formation and function require precise cardiac gene expression for cardiac myogenesis, morphogenesis and contractility. These growth processes are controlled by complex regulatory networks at the transcriptional level, through interactions between transcription factors and their corresponding DNA binding sequence motifs (enhancer/promoter elements) [2] . Many cardiac-expressed transcription factors, such as myocardin [3] , NKX2.5 [4] , MEF2C [5] , and GATA4 [6] , have been shown to influence cardiomyocyte differentiation and cardiac gene expression during heart development. microRNAs (miRNAs) have recently elicited remarkable interest as central regulators of gene expression during normal biological growth, as well as how variations in their levels associate with human disease. These small non-coding RNAs are evolutionarily conserved and act at the post-transcriptional level as "fine tuners" and/or "safeguards" to balance dramatic environmentally induced alterations in gene expression and maintain the homeostasis of organisms. Many miRNAs are expressed in a tissue-specific manner. Cardiac and skeletal specific miRNAs, miR-1, miR-133, miR-206, miR-208 and miR-499 have been shown to regulate muscle development and function. In addition, many miRNAs are expressed and function in biologically context-relevant manner. For example, miR-17-92 cluster is called "oncomiR" because of its high expression and involvement in cancer. Here, we review recent literature in the burgeoning miRNA field and focus on the roles of miRNAs during cardiovascular development and disease.
The discovery, transcription, processing and maturation of miRNAs miRNAs are noncoding RNAs of ~22 nucleotides that negatively regulate gene expression by reducing mRNA stability and/or inhibiting translation [7] . The first miRNA was discovered in 1993, encoded by the lin-4 gene. Lin-4 regulates the timing of C. elegans larval development by suppressing lin-14 protein expression without affecting lin-14 mRNA levels [8, 9] . To this date, the miRNA online database (miRBase 16) contains over 15,000 miRNA gene loci from over 140 species, and over 17,000 distinct mature microRNA sequences including estimated thousands of miRNAs encoded in human [10, 11] . According to the location of miRNA-encoding genes in the genome, miRNAs can be categorized into intergenic, intronic and exonic miRNAs. Intergenic miRNA genes are located between two protein-coding genes and employ their own promoters and regulatory units. Intronic and exonic miRNA genes are located within intron and exon regions, respectively, of genes and are co-transcribed with their hosts. Some intronic miRNAs also have their own cis-elements to direct the transcription of the miRNA genes in the opposite orientation of their host genes [11] . miRNA biogenesis begins with the transcription of primary miRNAs (pri-miRNAs) by RNA polymerase II as long transcripts. In the nucleus, the pri-miRNAs are cleaved by RNAse III endonuclease Drosha and the dsDNA-binding protein DGCR8 to produce ~70-nt long intermediate precursor-miRNAs (pre-miRNAs) with a characteristic stem-loop structure [12, 13] . Pre-miRNAs are then exported to the cytoplasm by exportin-5 [12, [14] [15] [16] [17] [18] and further cleaved by Dicer, another RNAse III endonuclease [19] [20] [21] [22] . The resulting ~22-nt mature miRNA duplex is released by Dicer and a single stem-arm (the guiding strand) is incorporated into the RNA-induced silencing complex (RISC), which recognizes specific targets by binding to their 3' untranslated regions (3'UTRs) and induces post-transcriptional gene silencing [23] . In some cases, miRNAs are also known to bind to the 5' untranslated regions (5'UTRs) and the coding sequences, or the open reading frames, of their target genes.
Global role of miRNA in cardiovascular development
Dicer, an endoribonuclease of the RNase III family, is required for the maturation of most (if not all) miRNAs. In mice, genetic deletion of Dicer resulted in the depletion of functional mature miRNAs. Dicer null mice are developmentally arrested during gastrulation which results in early embryonic lethality [24] . Additional studies showed that loss of Dicer in murine embryonic stem (ES) cell compromised their proliferation [25] . Similarly, in zebrafish, dicer mutants showed abnormal morphogenesis during gastrulation and display defects in somitogenesis and heart development [26, 27] . These compelling pieces of evidence from genetic studies clearly demonstrate that miRNAs are indispensable for animal development.
To better understand the role of miRNAs in cardiovascular development and function, conditional targeting of the Dicer gene using the Cre-LoxP system in the cardiovascular system was conducted. Conditional deletion of Dicer using a Cre-recombinease controlled by the Nkx2.5 promoter, which directs Cre expression in cardiac progenitor cells as early as embryonic day 8.5 (E8.5), led to embryonic lethality at E12.5 with abnormal heart morphogenesis [28] . Cardiac-specific deletion of Dicer during later development, using a Cre-recombinease under the control of α-myosin heavy chain (MHC) promoter (which is highly expressed in the cardiomyocytes of postnatal hearts) results in dilated cardiomyopathy, heart failure and postnatal lethality. The heart of mutant mice exhibited aberrant expression of cardiac contractile proteins and displayed profound sarcomere disarray, though the patterning of the mouse heart appeared unaffected [29] . Cardiacspecific deletion of Drosha, another enzyme essential for miRNA processing, led to similar defects in the heart, further highlighting the importance of miRNAs in heart development and function [30] . Similarly, Cre-loxP-mediated deletion of Dicer in vascular smooth muscle (VSM) resulted in late embryonic lethality around E16 to E17 due to decreased smooth muscle cell (SMC) proliferation and differentiation. Mutant embryos exhibit thinner vessel walls, impaired contractility, and hemorrhage [31] . Interestingly, conditional deletion of Dicer in embryonic neural crest cells (NCCs) using Wnt1-Cre resulted in substantial defects in NCC-derived structures including aortic arches, outflow tracts and ventricular septum, in addition to profound craniofacial defects [32] . Together, these studies clearly established crucial roles for miRNAs during cardiovascular development (Fig. 1 ).
Bicistronic miR-1/ miR-133 clusters
miR-1 is the most abundantly expressed miRNA in the heart and was also the first miRNA documented as essential for cardiac development [28, 33] . In vertebrates, members of the miR-1 (miR-1-1, miR1-2, miR-206) and miR-133 (miR-133a-1, miR-133a-2, miR-133b) families are generated as pairs from the same bicistronic transcripts. miR-1-1/miR-133a-2 are clustered in an intergenic region of mouse chromosome 2 whereas the miR-1-2/ miR-133a-1 cluster is located in the anti-sense orientation within an intron of the Mib1 gene on chromosome 18. The expression of miR-1 and miR-133a is cardiac and skeletal-muscle specific. The related miR-206 and miR-133b genes are encoded on mouse chromosome 1 and are specifically expressed in skeletal muscle [34] . Well-known muscle transcriptional networks, consisting of SRF/myocardin and MyoD/MEF2 for cardiac and skeletal muscle gene expression, respectively, are responsible for the expression of these miRNA genes [33] [34] [35] . In the heart, SRF binds the enhancer regions of the miR-1/miR-133 cluster and regulates their expression in cardiomyocytes [33, 36] . In skeletal muscle, MEF2 cooperates with MyoD to bind an intronic enhancer of the miR-1/miR-133 cluster to activate the transcription [34, 37] . Similarly, SRF regulates cardiac-specific expression while MEF2 controls the expression of miR-1 in skeletal musculature through cooperation with the basic helix-loop-helix (bHLH) transcription factor Twist in Drosophila [38, 39] . The highly conserved regulation of miR-1/miR-133 expression by tissue-specific transcription factors implies a critical role for miR-1/miR-133 in the complex and precise process of cardiac and skeletal muscle development.
Gain-and loss-of function studies revealed that miR-1/miR-133 play crucial roles in mouse hearts. Overexpression of miR-1 under the control of the cardiac-specific promoter βMHC in transgenic mice leads to a thin ventricular wall and embryonic lethality at E13.5, in part due to defective ventricular myocyte proliferation [33] . Consistent with this observation, introduction of miR-1 into developing Xenopus embryos interfered with heart development [34] . Similarly, miR-1 negatively regulates cell proliferation in skeletal muscle [34] and smooth muscle cells [40] . One of the validated targets of miR-1 in the heart is Hand2, a bHLH transcription factor involved in ventricular myocyte expansion. Interestingly, Hand2 mutant mice display similar phenotypes as do miR-1 transgenic mice [33, 41] . Complementing the overexpression studies of miR-1, Zhao et al. targeted the mouse miR-1-2 gene, one of the two miR-1 genes sharing identical sequence in their mature forms [28] . The deletion of miR-1-2 resulted in embryonic lethality starting at E15.5 in about 50% mutant embryos, in part due to a ventricular septal defect (VSD). Surviving mutant mice often die suddenly due to conduction system defects with a prolonged QRS complex and shortened PR delay [28] . Consistently, the expression of its target Hand2 is elevated in miR-1-2 null mice. The expression of IRX5 (Iroquois homeobox 5), another putative target of miR-1, is increased in the heart of miR-1-2 null mice, which is partially responsible for the arrhythmia and sudden death observed in the miR-1-2 mutant mice [28] . In skeletal muscle, miR-1 was found to promote myoblast differentiation [34] . However, deletion of miR-1-2 did not appear to affect skeletal muscle development by gross morphologic analysis. Such distinct requirement for miR-1 in cardiac versus skeletal muscle development could reflect a difference in tissue-specific genes that are targeted by this miRNA. Because of the different loci of miR-1-1 and miR-1-2 in the genome, the compound deletion of both miR-1-1 and miR-1-2 will be essential to elucidate the exact role of miR-1 in cardiac and skeletal muscle development.
Deletion of miR-133a-1 or miR-133a-2 alone (co-transcribed from the bicistronic miR-1/ miR-133 clusters) does not result in any obvious cardiac defect whereas compound deletion of both causes embryonic lethality in some animals, due to ventricular septal defects (VSDs). Surviving miR-133a compound null mice display dilated cardiomyopathy and heart failure [42] . Moreover, miR-133a mutant mice exhibit excessive cardiomyocyte proliferation with unregulated cyclin D2, a direct target of miR-133a [42] . Conversely, overexpression of miR-133a driven by the βMHC promoter in embryonic cardiomyocytes inhibits cardiomyocyte proliferation and causes embryonic lethality characterized by a thinner ventricular wall and VSD [42] . Results from these genetic studies indicate that miR-133a negatively regulates cardiomyocyte proliferation during heart development. In contrast to its function in cardiomyocytes, overexpression of miR-133 induces skeletal muscle myoblast proliferation, in vivo and in vitro [34] . The apparently distinct role of miR-133a in cardiac versus skeletal muscle further emphasizes the complexity of miRNA mediated regulation and highlights the vast array of their tissue specific targets that are regulated during development.
In addition to being expressed in cardiac and skeletal muscle during development, miR-1 and miR-133 are expressed in ES cell derived cardiomyocytes [43] . Interestingly, miR-1 and miR-133, when overexpressed in ES cells, suppress their differentiation into endodermal or ectodermal lineages in vitro, in addition to promoting cardiomyocyte differentiation [43] . It is not clear whether miR-1 or miR-133 participate in the regulation of embryonic germ layer specification during gastrulation in vivo.
A genome-wide screen was conducted in Drosophila to define the function and molecular mechanism of fly miR-1 (dmiR-1), taking advantage of the powerful genetic approaches available with this model. As envisioned, these studies identified novel genetic pathways in which miR-1 functions. King et al identified kayak, which encodes a developmentally regulated transcription factor, as a dmiR-1 target. They further revealed a previously unappreciated function of dmiR-1 in regulating cell polarity during Drosophila cardiogenesis [44] . Supporting this finding, kayak's mammalian homologue c-Fos, which is an immediate early response gene, was found to be dysregulated in the heart of miR-1 transgenic and knockout mice in response to thoracic aortic banding-induced cardiac stress [44] . In another study, Qian et al. discovered Cdc42, a Rho-GTPase, genetically interacts with Tinman (Drosophila)/Nkx2-5 (mammalian) to regulate heart function. It turned out that the 3'UTR of the Cdc42 gene is a target of miR-1. Surprisingly, the expression of miR-1 is negatively regulated by Nkx2.5 [45] . Together, these studies highlight the wide spectrum of functional involvement of miRNAs in the heart.
Cardiac myomiR families (miR-208a, miR-208b, miR-499)
There are two major myosin heavy chain (Myh) genes expressed in the heart, αMHC (Myh6) and βMHC (Myh7). The ratio of αMHC and βMHC affects contractility of the cardiac sarcomeres and cardiac energy consumption since they have distinct rate of converting ATP to mechanical work [46] . In rodent hearts, the slower isoform βMHC is specifically expressed in embryonic and fetal stages while the faster isoform αMHC is expressed predominantly in the adult heart. Whereas the developmental biology, genetics and physiology aspects of the MHC proteins have been extensively investigated for decades, only very recently did we surprisingly discover that miRNAs are "hiding" and encoded by introns within these MHC genes. Now we know that members of the miR-208 family, miR-208a, miR-208b, and miR-499 are encoded within introns of the Myh6, Myh7, Myh7b genes, respectively [47] . miR-208a and miR-208b are differentially expressed during heart development and in diseased hearts, paralleling the expression of their host genes, Myh6 and Myh7 respectively. These miRNAs participate in the regulation of the host gene switch during development and under stress conditions in a feedback manner [47] [48] [49] . Loss-offunction studies reveal that deletion of miR-208a in mice does not result in an obvious phenotype. miR-208a null mice are viable, fertile, with normal cardiac function, indicating that miR-208a is not required for cardiogenesis and embryonic development [48, 49] . However, under stress condition, miR-208a is required for stress-induced cardiac pathophysiological responses. miR-208a knockout mice were resistant to aortic constriction and transgenic calcineurin overexpression induced cardiac hypertrophy and fibrosis [49] .
Conversely, gain-of-function studies demonstrate that cardiac-specific miR-208a overexpression is sufficient to induce cardiac hypertrophy and induce cardiac conduction defects [48] . The reactivation of the fetal cardiac gene program is usually observed when the heart undergoes hypertrophy and heart failure under stress condition [50] . In miR-208a null mice, hypertrophic stress failed to upregulate the expression level of Myh7 whereas other stress-responsed gene, like Nppa and Nppb was elevated [49] . Consistently, overexpression of miR-208a induced Myh7 gene expression [48] , suggesting that miR-208a helps regulate the switch of Myh6/Myh7 in response to hormonal and mechanic stimuli. Besides controlling the expression of the Myh7/miR-208b duo, miR-208a also acts upstream of Myh7b/miR-499 in adult hearts since miR-208a null mice lack the expression of the latter two miRNAs [47] . One of the verified targets of miR-208a is Thrap1 (thyroid hormone receptor-associated protein 1), which is a key component of the thyroid hormone signal pathway. Deletion of miR-208a resulted in an increase in THRAP1 expression and enhanced thyroid hormone receptor mediated suppression of Myh7 [48, 49] . Thus, the miR-208a/ Thrap connection may explain why miR-208a and thyroid hormone are involved in cardiac hypertrophy. In addition, other miR-208a targets including Gata4, Cx40 and Hopx, are important regulators of cardiac gene expression and heart function. They all likely contribute to the function of miR-208a. Together, these studies demonstrate that miR-208a plays important roles in the cardiac stress response and remodeling [48] .
The miR-17-92 cluster promotes cardiac progenitors differentiation
The miR-17-92 cluster is a polycistronic miRNA gene located in the third intron of the primary transcript C13orf25 on human chromosome 13, a region frequently links to lymphoma and solid tumors [51] . The miR-17-92 cluster cotranscribes six mature miRNAs including miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1, which are highly conserved in their sequences and organization among all vertebrates [51] . The Hannon and Hammond laboratories firstly demonstrated that miR-17-92 could modulate tumor formation and therefore named the cluster OncomiR-1 [52] . Despite the well-known involvement of the miR-17-92 cluster in tumorigenesis, recent mouse genetic studies reveal that this miRNA cluster is essential for cardiac development and function. Ventura et.al generated null mice for the miR-17-92 cluster as well as its paralogs miR-106b-25 and miR-106a-363 [53] . Complete deletion of the miR-17-92 cluster resulted in smaller embryos and perinatal lethality. Mutant animals displayed thin ventricle walls, ventricular septal defects (VSDs) and lung hypoplasia. Whereas deletion of the other two paralogs individually did not affect heart development or survival, compound loss of either miR-106b-25 or miR-106a-363 with miR-17-92 leads to embryonic lethality with higher penetration than miR-17-92 deletion alone. Together, these studies establish the primary effect of the miR-17-92 cluster in cardiac development in a dose-dependent manner with the other two paralogs [53] .
Most recently, Wang et al. documented evidence to suggest that the miR-17-92 cluster could mediate myocardial differentiation of cardiac progenitors in the secondary heart field [54] . It was further demonstrated that the Bmp signaling pathway governed the silencing timing of progenitor genes, Isl1 and Tbx1 in the outflow tract. This is achieved by regulating miR-17-92 expression through Smad-mediated pri-miRNA transcriptional activation. Increased expression of the miR-17-92 cluster (predominantly miR-17 and miR-20) then directly targets ISL1 thereby repressing the emergence of cardiac progenitors in secondary heart field and eventually affecting differentiation of the outflow tract [54] . From those studies, we have learned that miRNAs participate in the regulation of cell proliferation and differentiation and that they integrate into multiple signaling pathways and transcriptional networks to modulate heart development.
Regulation of cardiac patterning by miR-138
Heart development requires precise coordination of cell fate determination, pattern formation and cell movement [55] . In these highly conserved events, transcriptional networks accurately control specific gene expression in a spatial and/or temporal manner [56] . It is not surprising that recent investigations revealed that miRNAs regulated cardiac patterning. In zebrafish, the atrioventricular canal (AVC) specifically expresses cspg2, notch1b and tbx2 which distinguish its expression profile from atrium and ventricle [57, 58] . Morton et al. found that miR-138 is expressed in specific domains of the zebrafish heart and is required to establish appropriate chamber-specific gene expression patterns [59] . Disruption of miR-138 by morpholino and antagomir in zebrafish embryos led to expansion of AVC-restricted genes to the ventricular chamber. As a result, ventricular cardiomyocytes failed to fully mature. These observations suggest that miR-138 regulates cardiac patterning during heart development by restricting AVC gene expression. Mechanistically, miR-138 directly targets both cspg2 and retinoic acid dehydrogenase (ALDH1a2), resulting in reduced retinoic acid activity, which positively regulates cspg2 expression [59] . Whereas the study from zebrafish documented an interesting function of miR-138 during cardiac morphogenesis, genetic studies in mammalians will be critical in order to more definitely assign the function for this miRNA in vivo. Given the need for the precise and intricate regulation of gene expression during heart development, it is reasonable to predict that additional miRNAs will be associated with the complex regulatory networks that control cardiac development and patterning.
miRNAs in cardiac regeneration, remodeling and disease
The mammalian adult heart is generally viewed as a terminally differentiated organ with no or very limited regenerative ability upon injury or stress induced loss of tissue. The cardiomyocytes of embryonic and neonatal hearts continue to proliferate; however, this regenerative potential is lost in mouse and rat hearts seven days after birth when cardiomyocyte proliferation is arrested [60] . By screening the expression patterns of miRNAs between postnatal day1 and day10 in wild type neonatal rat cardiomyocytes, Porrello et al. identified members of the miR-15 family, including miR-195, miR-15a, miR-15b, miR-16 and miR-497, as key regulators of postnatal cardiomyocyte mitotic arrest [61] . Using both gain-and loss-of-function approaches, it was demonstrated that the miR-15 family inhibits cardiomyocyte proliferation by repressing the expression of multiple cell cycle regulators, including the checkpoint kinase 1 (Chek1) [61] . Consistent with its role in regulating mitosis, the miR-15 family was shown to be upregulated in cardiac ischemia and heart failure [62] . Another study showed that the miR-15 family induces apoptosis by targeting antiapoptotic factor Bcl2 [63] . Transgenic overexpression of miR-195, another member of the miR-15 family, in embryonic or postnatal hearts using βMHC and aMHC promoters, respectively, resulted in cardiac hypertrophy associated with dilated cardiomyopathy [61, 62] . All these studies suggest that the miR-15 family of miRNAs induce cardiomyocyte apoptosis and, therefore, serve as negative regulators of cardiac regeneration in response to stress.
In contrast to the upregulation of the miR-15 family, miR-320 was downregulated following ischemia/reperfusion injury. Unexpectedly, cardiac-specific overexpression of miR-320 induced myocardial apoptosis and increased infarct size, whereas knockdown of endogenous miR-320 by antagomirs led to cardiac protection in infarct models. The function of miR-320 was mediated at least in part, by its target gene, heat-shock protein 20 (hsp20) [64] . This study taught us that the expression pattern of a miRNA does not necessarily correlate with its function. In addition, several other miRNAs, including miR-21 [65] , miR-24 [66] and miR-499 [67] , appear to exhibit cardioprotective effects by decreasing apoptosis of cardiomyocytes. However, the significance of such an effect and its molecular mechanism remain to be further understood.
One of the major responses of the heart to pathologic stress is extensive cardiac hypertrophy, which often leads to end stage heart failure. The expression of many miRNAs was dysregulated during cardiac hypertrophy [62, 68, 69] ; for example, miR-214 is upregulated during hypertrophy. However, transgenic mice overexpressing miR-214 do not exhibit an abnormal cardiac phenotype [62] . miR-21 was also upregulated in heart failure and under stress conditions. Knockdown of miR-21 by an antagomir was shown to prevent cardiac hypertrophy and fibrosis in response to pressure overload [70] . However, these promising results were not supported by genetic evidence. Genetic deletion of miR-21 from mouse does not prevent cardiac hypertrophy, fibrosis and stress-responsive gene expression, indicating miR-21 is not essential for the pathological remodeling of the heart [71] . The basis for the discrepancy between these studies is not clear, although off-target effects of the antagomirs is one possibility.
Unlike miR-195, miR-214 or miR-21, the expression of miR-1, miR-133a, miR-93 and miR-181 is downregulated during cardiac hypertrophy [62, 72, 73] . Further studies showed that repression of miR-133a is sufficient to cause cardiac hypertrophy both in vivo and in vitro, likely via the upregulation of RhoA, Cdc42, and NELFA/Whsc2 [72] . In contrast, genetic deletion of both miR-133a-1 and miR-133a-2 resulted in partial embryonic lethality while surviving mutant mice displayed dilated cardiomyopathy with no sign of cardiac hypertrophy [42] , raising the concern of how we reconcile the differences between experimental approaches. Although miR-208 has not been shown misexpressed in cardiac hypertrophy, both gain-and loss-of-function studies clearly establish that miR-208 is required and sufficient for cardiac hypertrophy in response to stress [48, 49] . It is now well appreciated that miRNAs are not only indispensable for normal cardiovascular development, but that they are essential elements that regulate cardiac remodeling during cardiovascular disease.
Vascular smooth muscle cell (VSMC)-enriched miR-143/145 cluster
Vascular smooth muscle cells (VSMCs) are a specialized cell type within the tunica media of arteries, known to regulate arterial tone and blood pressure. VSMCs are of mesodermal origin and are highly proliferative and migratory during early embryonic vasculogenesis [74] . In adult blood vessels, differentiated smooth muscle cells (SMCs) become quiescent and contractile, which is associated with expression of SMC-specific genes, such as SM α-actin, SM-MHC, SM22α and calponin (Fig. 2) . However, unlike terminally differentiated cardiac and skeletal muscle cells, SMCs have high plasticity in response to injury by switching from a contractile phenotype to an alternate state that facilitates proliferation, migration and collagen production. Such phenotypic switching is known to contribute to vascular diseases, such as atherosclerosis, restenosis after angioplasty, and hypertension [74] . Increasing numbers of studies have demonstrated that miRNAs play key roles in SMC phenotypic regulation. Several miRNAs, including miR-21 [75] , miR-24 [76] , miR-221/222 [77] and miR-1 [40] have been implicated in the regulation of gene expression in SMCs. SMC specific miR-143 and miR-145, however, draw the most attention [78] [79] [80] [81] [82] .
MiR-143 and miR-145, encoded on chromosome 18 in mouse and on chromosome 5 in human, are transcribed as a cluster despite their distinct sequences. miR143/145 are expressed in cardiac progenitor cells as earlier as E7.5 [78, 80] but their cardiac expression is turned off at late stage of E16.5, leaving its expression exclusively confined to vascular and visceral SMCs [78, 80, 82] . It is well-documented that the transcription factor SRF interacts with the muscle cell-specific cofactor myocardin to bind the CArG box (CC(AT) 6 GG) to modulate SMC-specific gene expression and SMC development [3, 83] . Given their SMC-specific expression pattern, it is not surprising that within the upstream enhancer region of the miR-143/145 genes, there are highly conserved CArG boxes to mediate this SRF/myocardin dependent regulation of miR-143/145 expression in SMCs [78, 80] . Results from in vitro studies suggest that miR-143/145 regulate smooth muscle cell fate and plasticity. Cordes et al. reported that miR-145 but not miR-143, is sufficient to drive undifferentiated neural crest stem cells into the VSMC lineage, defined by the expression of VSMC differentiation genes [80] . miR-145 has also been shown to potentiate myocardindependent conversion of fibroblasts into VSMCs, although neither miR-145 nor miR-143 alone was sufficient for this reprogramming [80] . MiR-143/145 cooperatively target a network of transcription factors to regulate differentiation and proliferation of VSMCs; miR-143 targets Elk1 (a SRF co-factor and an activator of VSMC proliferation), and miR-145 targets myocardin, Klf4 and calmodulin kinase II-delta (the later two are both positive regulators of cell proliferation) [80] (Fig. 2) . Notably, miR-145 increases myocardin expression level, which is in sharp contrast to many miRNAs that repress their targets. However, the molecular mechanism by which miR-145 activates its target gene expression remains unclear.
In the SMCs comprising injured and atherosclerotic vessels, the expression of miR-143 and miR-145 is dramatically downregulated [79] [80] [81] . Restoration of miR-143 and miR-145 reduced ballon-injury induced neointimal hyperplasia [79, 81] . In cultured VSMCs, miR-143 and miR-145 are also downregulated during cell dedifferentiation. Conversely, induction of miR-143 and miR-145 reduces VSMC proliferation and promotes differentiation [79] [80] [81] . These in vitro studies suggest that miR-143/145 may play key roles in controlling the SMC phenotypic switching. However, such conclusion is not fully backed up by in vivo evidence. Using a genetic approach, three laboratories independently reported that knockout of either miR-143 or miR-145 alone or both miR-143/miR-145 did not affect development. Double knockout mice are viable without any obvious disorders, indicating that these two miRNAs are dispensable for VSMC fate specification or vessel development in vivo [79, 80, 82] . Nevertheless, the deletion of miR-143/145 does cause abnormalities in postnatal VSMC. miR-143/145 KO mice are hypotensive with thinning of the tunica media of aorta and femoral artery [78, 79, 82] . VSMCs in these mice appear to be locked in the synthetic state without contractile ability. The mutant mice further developed neointimal lesions in the femoral arteries in old age [82] . Additionally, miR-143/145 null mice display defects in cytoskeletal assembly with disarray of actin stress fibers, leading to diminished migration activity in SMCs [78] . Boettger et al. performed high-throughput proteomics screening for miR-143/145 targets and they identified angiotensin-converting enzyme (ACE), which affects the contractility of blood vessel, as a miR-145 target [82] . Intriguingly, in miR-145 KO or miR-143/145 dKO mice, neointimal lesion development was impeded after arotid artery ligation [78] . This is in sharp contrast with the results from in vitro studies in which the inhibition of miR-145 with an antisense oligonucleotide blocked smooth muscle cell differentiation [80] [81] [82] . The disparities may due to the biological context and complex compensatory mechanisms involving miR-143/145 during VSMC development. Such discrepancy also highlights the importance of genetic modeling to attain an in depth understanding of the function of miRNAs in development and diseases.
Regulation of angiogenesis by angiomiRs
Angiogenesis is characterized by the formation of new vessels originating from existing vessels, a process critical for vascular development and homeostasis. Aberrant angiogenesis is associated with cancer (increased angiogenesis) and ischemia (decreased angiogenesis). Angiogenesis primarily involves endothelial cell proliferation, migration and lumen formation as well as vessel maintenance. Recent studies have identified miRNAs as key regulators of this process and endothelial cell function. Tissue-specific Dicer deletion revealed the global requirement of miRNAs in angiogenesis. It was reported that conditional deletion of Dicer in endothelial cells impaired embryonic and postnatal angiogenesis [84] [85] [86] . From miRNA profiling of human umbilical vein endothelial cells (HUVEC), miR-221/222, miR-21, the let-7 family, the miR-17-92 cluster, the miR-23-24 cluster, and miR-126 have been demonstrated to be highly expressed in endothelial cells [85] [86] [87] . To date, miR-126 is the best known endothelial cell-specific "angiomiR" that modulates angiogenic signaling and vascular integrity [88, 89] . miR-126 is located at intron 7 of the epidermal growth factor-like domain 7 (Egfl7) gene, which encodes an endothelial secreted factor that regulates embryonic vascular tube formation during zebrafish development [90] . Two independent studies using loss-offunction approaches highlighted the roles of mi-126 in vessel development in both mice and zebrafish [88, 89] . MiR-126 knockout mice and zebrafish morphants (created by morpholino knockdown) exhibit leaky vessels, hemorrhaging, and partial embryonic lethality [88, 91] . The surviving miR-126 knockout mice display reduced cardiac neovascularization, cardiac rupture and death of animals after myocardium infarction [88] . Mechanistically, miR-126 enhances the responses of endothelial cells to the angiogenic factors VEGF and FGF, which are mediated, at least in part, by promoting MAP kinase and PI3K signaling pathways through repression of the negative regulators Spred-1 and PIK3R2, respectively [88, 91] (Fig. 3) .
In a previous Egfl7 (the host gene of miR-126) loss-of-function study, both gene-trap and lacZ knock-in mice display edema, angiogenic defects, loss of vascular integrity, and embryonic lethality (~50%) [92] . Intriguingly, these phenotypes mimic those observed for the miR-126 knockout mice, including partial (50%) penetration for embryonic lethality, edema, defective cranial vessel and retina vascularication [88, 92] , raising the possibility that the vessel abnormalities in the Egfl7 knockout mice are attributed to the miR-126 deletion. The expression levels of both mRNA and protein of Egfl7 are not changed in miR-126 knockout mice, indicating that the miR-126 null phenotype is unlikely to be mediated by loss of Egfl7 function [88] . To further clarify this issue, Kuhnert et al generated two separate mouse lines using floxed alleles to more precisely and selectively delete Egfl7 (Egfl7 Δ ) or the miR-126 (miR-126 Δ ) gene without reciprocal perturbation in mice [91] . Unexpectedly, the Egfl7 Δ/Δ mice are phenotypically normal, whereas the miR-126 Δ/Δ mice recapitulate previously reported embryonic and postnatal vascular phenotypes in Egfl7 knockout mice. These results convincingly demonstrate that the previously reported vascular phenotypes associated with the deletion of Egfl7/miR-126 locus are solely attributed to the loss of miR-126 rather than the loss of Egfl7 [91, 92] . These surprising findings highlight the roles of non-coding miRNAs embedded within introns of protein-coding genes and emphasize the need to revisit genetic deletion studies in which intronic miRNAs were also deleted when the host genes were targeted. Clearly, a more precise "micro-deletion" is necessary to define the loss-of-function studies of miRNA and their host genes.
The miR-17-92 cluster, often referred to as "oncomiR-1", has previously been shown to promote tumor angiogenesis in vivo in a non-cell autonomous manner [93] . The proangiogenic activity of this miRNA cluster has been attributed to miR-18a/19 which directly represses the expression of the antiangiogenic thrombospondin-1 (TSP-1) and connective tissue growth factor (CTGF) in tumor cells. miR-18a/19 consequently promotes angiogenesis in adjacent tumor endothelium in a paracrine mechanism [93] . Intriguingly, recent studies also demonstrated that members of the miR-17-92 cluster exhibit a cellintrinsic anti-angiogenic function within endothelial cells [94, 95] . More importantly, antagomir inhibition of endogenous miR-92a increases neovascularization and rescues cardiac functional after myocardium infarction in mice [94] (Fig. 3) . These data reveal the complexity of miR-17-92 regulation of angiogenesis and a cell-type-context dependent mechanism. Given their opposite effects on different cell types, a more comprehensive paradigm needs to be considered when exploring the role of the miR-17-92 cluster on physiological and pathological angiogenesis and related cardiovascular disorders.
Looking forward
miRNA research is a rapidly emerging area within the larger field of "small" non-coding RNAs. These newly discovered regulators play "big" roles in the regulation of diverse biological function, from cell differentiation, proliferation and apoptosis, to pathophysiological conditions. miRNAs participate in almost all aspects of cardiovascular biology. However, we are only seeing the tip of the iceberg, with numerous unanswered questions on miRNA function and mechanism of acting hiding below the surface.
Very little is known about what exactly miRNAs do. Genetic approaches to study miRNA function, including knockout and transgenic overexpression approaches, are being used to establish the biological functions of miRNAs in animal models. Unfortunately, only a very few miRNAs have been knocked out in mice. Among those miRNA gene targeting mutants, some display partial embryonic lethality [28, 53, 88, 91] and the surviving mutants tend to be normal after they pass through the critical developmental stages. These studies indicate that individual miRNAs may not function as critical "on-off" switches; rather they more likely serve as "fine tuners" of gene expression in cardiac development. Given that a single miRNA could modulate hundreds of target genes and a single gene contains multiple miRNAs binding sites at its 3'-UTR, systematical analysis of the functionally grouped miRNAs and/or the polycistronic miRNA clusters, may confer deep insights into the role of miRNAs within the molecular network that control cardiac development and function. In the heart, it will be important to examine miRNAs in which their expression is controlled by key cardiac transcription factors such as Nkx2.5, Gata4, MEF2C, Myocardin, Tbx5 and others.
Identification of miRNA targets and understanding the miRNA-mRNA interaction are keys to elucidating the mechanisms of miRNA function. A general approach for miRNA target identification is mainly based on bioinformatic prediction with several criteria [96] . Experimental validation (such as luciferase reporter assays and Western blot analyses) will allow the confirmation of such targets. Comprehensive identification and quantitative analysis of miRNA targets in an unbiased manner employing in vivo biologically or physiologically relevant contexts are needed. A recently developed method that compares mRNAs recruited in the RISC complex between transgenic mice that overexpressed a miRNA (programmed RISCome) with wild type mice (WT RISCome) through next generation sequencing appears to be a very powerful approach for miRNA target identification [97] . More importantly, with the availability of high-throughput and unbiased screening technologies, "RISCing" the heart from miRNA knockout mice (deprogrammed RISCome sequencing) will provide more meaningful information by identifying biologically context relevant targets of miRNAs in vivo.
Certain miRNA expression signatures have been linked to human disease. Many miRNAs are stable and can be detected and quantitatively measured in the circulating system, making them putative markers for clinical diagnostics of human heart disease. In addition, the progression in the development of technologies by which miRNAs can be easily manipulated and synthesized, may provide therapeutic opportunities for heart diseases using miRNAs as pharmacological agents. With the explosion in enthusiasm for defining the roles of miRNAs in cardiac disease, we believe that the era of miRNA-based therapeutics is in the foreseeable future.
Highlights
• Current knowledge on miRNA function during cardiovascular development is reviewed.
• We briefly describe the discovery of miRNAs and their mechanism of action.
• miRNAs in cardiovascular development and physiology pathway is highlighted.
• The potential of miRNAs as therapeutic targets is discussed. 
